di-3-ANEPPDHQ from Molecular Probes (Invitrogen)
REact 2 Buffer from Invitrogen
Phosphate Colorimetric Assay Kit from R&D Systems
Feline IL-10 ELISpot Development Kit from R&D Systems
Biology Products:(Date:12/2/2009)...Newswire/ -- S*BIO Pte Ltd today announced data pr...18, at The American Society of Hematology 51st Ann...ata will be presented on the clinical results from...ling its safety, tolerability and pharmacokinetic/...ging from 100 to 600 mg. These doses were administ...
(Date:12/2/2009)...wire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ...maceutical company focused on endocrine therapy an... Drug Administration (FDA) has granted Fast Track ...ibitor compound, perifosine (KRX-0401), for the tr...eryx Biopharmaceuticals, Inc. ("Keryx") ( KERX), i...
(Date:12/2/2009)...ewswire/ -- According to the National Institute of...gnosed with diabetes already have some stage of di...to the retina caused by leaky blood vessels, is a ...nd is one of the most feared diabetic complication...ve had diabetes for 10 years or more will experien...
(Date:12/1/2009)...ewswire/ -- Reportlinker.com announces that a new ...ue: ,, Chromium - Global Market Trends ,...-Global-Market-Trends.html ,, Worldwide demand... steel, while growth in aerospace and industrial g... chromium metal. Environmental constraints and rap...
Breaking Biology Technology:S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 2AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 2Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 4Reportlinker Adds Chromium - Global Market Trends 2Reportlinker Adds Chromium - Global Market Trends 3Reportlinker Adds Chromium - Global Market Trends 4Reportlinker Adds Chromium - Global Market Trends 5Reportlinker Adds Chromium - Global Market Trends 6Reportlinker Adds Chromium - Global Market Trends 7Reportlinker Adds Chromium - Global Market Trends 8Reportlinker Adds Chromium - Global Market Trends 9